Mr. Thomas Smeenk reports

HEMOSTEMIX ANNOUNCES ITS AI STRATEGY

Hemostemix Inc. has released its webinar topic for Thursday, Aug. 21, 2025. Croom Lawrence, chief commercialization officer, Hemostemix, who completed executive education in artificial intelligence and health care at the Massachusetts Institute of Technology, will present the company's phased approach to embedding AI across its patient engagement, clinical research and corporate operations.

"This webinar will showcase how we are applying artificial intelligence to transform every aspect of Hemostemix into the world's first AI-driven autologous stem cell therapy company treating pain associated with no-option patients who can be treated under Florida's SB1768," stated Thomas Smeenk, chief executive officer.

"We know the future of regenerative medicine is physician-based AI-enabled workflows," said Mr. Lawrence. "AI-based workflows generate a better patient experience, generates better recruitment, faster trials, best-in-class analytics, stronger patient outcomes and more efficient patient care," Mr. Lawrence said.

Patient care innovations

Health Insurance Portability and Accountability Act-compliant precision medicine diagnostics: The platform unifies patient records, medications, co-morbidities, genetics, gut microbiome and lifestyle data (exercise, diet and consumption patterns) into a single artificial-intelligence-powered analysis. This helps physicians see the patient's full health journey while showing patients how lifestyle choices impact outcomes.

Acurist.AI for early cognitive decline: Leveraging mild cognitive impairment screening, Hemostemix sets baseline assessments to monitor subtle memory changes before and after VesCell (ACP-01) treatment. Get yours today.

Artificial-intelligence-powered patient engagement: Around-the-clock personalized chatbot support improves access and satisfaction while securely guiding patients through treatment, recovery and lifestyle adjustments.

Patient decision support tools: Artificial-intelligence-driven insights assist physicians and health care coaches in tailoring plans that help patients sustain healthier habits following VesCell therapy.

Clinical and scientific advancement

Accelerated research with AI: Under physician and research oversight, AI tools analyze patient data to predict treatment responses and refine VesCell (ACP-01) trial design.

Predictive analytics for VesCell outcomes: Focused to the patient, the therapy success rate will be modelled based on co-morbidities, lifestyle patterns and epigenetic markers.

AI for trial matching: Intelligent agents streamline recruitment by rapidly screening patient profiles against trial criteria, accelerating enrolment and on-boarding.

Operational efficiency

Automated administrative workflows: HubSpot-integrated AI agents manage scheduling, billing and follow-ups, reducing overhead by up to 20 per cent.

AI-optimized resource allocation: It dynamically adjusts staffing, production and supply chains in line with forward-sold therapy demand -- therapy convertible debenture -- sales cycles.

Unified data ecosystem: A secure cloud-based system connects clinical trial data and outcome metrics, ensuring seamless Health Insurance Portability and Accountability Act-compliant access.

Pro-active compliance and security: Real-time AI monitoring detects risks and enforces data protection protocols to safeguard sensitive health information.

Webinar details:

• Date: Thursday, Aug. 21, 2025;
• Time: 12 p.m. EST;
• Format: webinar.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, and is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb-threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, the University of British Columbia and the University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years as a midpoint result.

We seek Safe Harbor.